BioSpace News Archive

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Matt Manders assumes leadership of government business as president, government and solutions of Cigna Corporation

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”).

MannKind Corporation announced that James S. Shannon, M.D., MRCP has been named the new Chairman of the Board of Directors effective December 9, 2020.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three decades of commercial experience, to its Board of Directors.

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the new data from its Phase 3 PROTECTIVE-2 Study 106 demonstrating that plinabulin in combination with pegfilgrastim offers greater protection against chemotherapy-induced neutropenia (CIN) than the standard of care, pegfilgrastim alone.

NeurAegis, Inc., a neuropharmaceutical company developing breakthrough treatments for neurological disorders, today announced the inaugural members of its Scientific-Medical Advisory Board who will help advance the Company’s preclinical and clinical development activities and product pipeline.

INOVIO (NASDAQ: INO), and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), today announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China.

First publication based on Phase III data to document sustained and clinically meaningful bilateral improvement in visual acuity from unilateral injection of a gene therapy